Fig. 3: Treatment with cilta-cel or ide-cel and correlation with clinical characteristics and outcome. | Nature Communications

Fig. 3: Treatment with cilta-cel or ide-cel and correlation with clinical characteristics and outcome.

From: Immune correlates of anti-BCMA CAR-T products idecabtagene vicleucel and ciltacabtagene autoleucel in a real-world cohort of patients with multiple myeloma

Fig. 3

A Bar graphs show absolute and relative dose levels received (blue = cilta-cel, N = 23; red = ide-cel, N = 16). Statistical differences between groups were calculated using a two-sided Mann-Whitney U test. B Depth of response at one and three months post-CAR-T, respectively. C Clinical course of patients receiving cilta-cel (blue) or ide-cel (red). D Progression-free survival (PFS) after treatment with cilta-cel or ide-cel. E Depth of response at 3 months post CAR T across both patient groups (N = 37) in relation to peak expansion levels of total, CD4 + , and CD8 + CAR-T. Bar graphs indicate median values with 95% confidence intervals (CI). Statistical differences between response categories were calculated using a Kruskal-Wallis test (one-way ANOVA on ranks). Source data are provided as a Source Data file.

Back to article page